

Special Issue

Plasma Proteomics Analysis Predicts Cancer Biomarkers

Message from the Guest Editors

We welcome contributions that attend the following areas of interest:

- Novel plasma proteomics techniques and technologies for cancer biomarker discovery;
- Identification and validation of plasma-based biomarkers for various types of cancers;
- Role of plasma proteomics analysis in early cancer detection and diagnosis;
- Functional characterization of plasma-derived cancer biomarkers;
- Translational applications of plasma proteomics in cancer management, including prognosis, prediction, and therapeutic monitoring;
- Integration of plasma proteomics data with other omics data for multi-dimensional cancer biomarker analysis;
- Bioinformatics and computational approaches for data analysis and interpretation in plasma proteomics-based cancer biomarker research;
- Challenges and opportunities in the field of plasma proteomics analysis for predicting cancer biomarkers;
- Clinical implementation and commercialization of plasma proteomics-based cancer biomarkers;
- Future directions and perspectives in the field of plasma proteomics analysis for cancer biomarker prediction.

Guest Editors

Dr. Seong Beom Ahn

Macquarie Medical School, Macquarie University, Macquarie Park, NSW 2109, Australia

Dr. Abidali Mohamedali

Department of Molecular Sciences, School of Life Sciences, Macquarie University, Macquarie, NSW 2109, Australia

Deadline for manuscript submissions

closed (30 June 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/171223

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)